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Abstract
Background: Administration of interferon-a (IFN-a) represents an approved adjuvant therapy as reported for malignancies
like melanoma and several viral infections. In malignant diseases, tolerance processes are critically involved in tumor
progression. In this study, the effect of IFN-a on tolerance induction by human tolerogenic dendritic cells (DC) was analyzed.
We focussed on tolerogenic IL-10-modulated DC (IL-10 DC) that are known to induce anergic regulatory T cells (iTregs).
Methodology/Principal Findings: IFN-a promoted an enhanced maturation of IL-10 DC as demonstrated by upregulation
of the differentiation marker CD83 as well as costimulatory molecules. IFN-a treatment resulted in an increased capacity of
DC to stimulate T cell activation compared to control tolerogenic DC. We observed a strengthened T cell proliferation and
increased IFN-c production of CD4
+ and CD8
+ T cells stimulated by IFN-a-DC, demonstrating a restoration of the
immunogenic capacity of tolerogenic DC in the presence of IFN-a. Notably, restimulation experiments revealed that IFN-a
treatment of tolerogenic DC abolished the induction of T cell anergy and suppressor function of iTregs. In contrast, IFN-a
neither affected the priming of iTregs nor converted iTregs into effector T cells.
Conclusions/Significance: IFN-a inhibits the induction of T cell tolerance by reversing the tolerogenic function of human
DC.
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Introduction
The type 1 interferon IFN-a is naturally produced in viral and
non-viral infections. It displays well-known antitumor activity [1],
but even more important, multiple immunoregulatory activities
have been described. Immune regulation by IFN-a includes
effects on proliferation, survival and differentiation of T and B
lymphocytes and cytoxicity of natural killer cells [2]. In addition,
IFN-a promotes maturation, functional activity and motility of
dendritic cells (DC) [3,4]. Hence, multiple protocols have been
established to promote the differentiation of DC by IFN-a in
combination with various stimuli such as proinflammatory
cytokines or TLR ligands as LPS [5,6].
Theeffectsoftype1interferonsareemployedintherapiesofsevere
viral infections, multiple sclerosis, myelo- and lymphoproliferative
diseases as well as solid tumors like malignant melanoma [7,8].
Melanoma represents the most malignant skin cancer with rising
incidence during the last decades in white populations worldwide [9].
The high risk of metastasis accounts for the need of adjuvant therapy
in early tumor stages. To date, IFN-a therapy represents the only
effective adjuvant therapeutic approach against malignant melanoma
as demonstrated in several studies. Nevertheless, effects of IFN-a on
tumor-associated tolerance are not understood [10].
In malignant diseases, induction of tolerance by tumor-derived
factors is one critical mechanism involved in tumor progression.
The production of the immunosuppressive cytokine IL-10 by
tumor cells themselves or by tumor-infiltrating immune cells is well
known for malignant melanoma and other tumor entities
[11,12,13,14]. IL-10 modulates the biologic function of antigen
presenting cells (APC) and of T cells [15]. In previous studies, we
and others demonstrated that IL-10 induces a tolerogenic
phenotype of DC (IL-10 DC) with impaired T cell stimulatory
properties [16,17,18]. Furthermore, IL-10 DC have been shown
to induce anergic regulatory CD4
+ and CD8
+ T cells (iTregs),
which inhibit activated cytotoxic and helper T cells, resulting in a
failure to kill melanoma cells [17,19].
Human DC comprise a heterogeneous cell population and their
functional potential depends on their origin, the cytokine
microenvironment and cell/cell interactions. They are central in
inducing immunity and in mediating immune tolerance in their
role as professional antigen-presenting cells. Tolerogenic DC
control the immune homeostasis and prevent the development of
autoimmune diseases but are also involved in tumor development
and progression [20].
We hypothesized that IFN-a may interfere with tumor-
associated tolerance mechanisms. In the present study, we
demonstrate that IFN-a abrogates the tolerogenic function of
human IL-10 DC and thereby prevents the induction of T cell
anergy and, subsequently the differentiation into suppressive
iTregs. The efficacy of IFN-a treatment in cancer and infectious
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associated tolerance induction.
Results
IFN-a enhanced the maturation of tolerogenic IL-10DC
IFN-a was shown to promote maturation of DC in various
settings [3,4,5,6]. Here, the effect of IFN-a on the function of
human tolerogenic DC was analyzed. We focussed on monocyte-
derived tolerogenic IL-10 DC as inducers of anergic iTregs
[16,17].
First, in dose-dependent experiments concentrations of 10
2–
10
4 U/ml IFN-a were identified to be effective in immune
modulation without toxic effects (data not shown). To assess the
effects of IFN-a on tolerogenic IL-10-modulated DC, IL-10 DC
were incubated with IFN-a for two days during final maturation.
We did not find an altered expression of MHC class II (HLA-DR)
and CD86 molecules after IFN-a treatment (data not shown,
Figure 1A, B). In contrast, expression of CD80 and CD83 was
significantly augmented on IFN-a-treated IL-10 DC (Fig. 1A, B),
demonstrating that IFN-a partially overcomes the tolerogenic
properties of IL-10 DC during DC differentiation. No alteration of
the phenotype of mDC was observed after IFN-a treatment during
terminal maturation (data not shown).
Cytokine production of DC is critically involved in T cell
priming and differentiation. Bioactive IL-12 represents an
important cytokine by which DC stimulate outgrowth and
activation of Th1/Tc1 cells, whereas the IL12p40 subunit also
dimerizes with the p19 subunit to form IL-23 or mediates
immunosuppressive functions [21,22]. In our study, we found that
IFN-a treatment of IL-10 DC as well as control mDC resulted in a
significant reduction or complete inhibition of IL-12 p40 secretion,
Figure 1. Immunophenotype of IL-10 DC after IFN-a treatment. (A, B) Immature DC were stimulated at day 5 of culture with a maturation
cocktail (mDC) or a maturation cocktail supplemented with IL-10 either with or without 10
4 U/mL IFN-a. (A) Dot plots of one representative
experiment and (B) expression of surface molecules of DC of 6 independent experiments are depicted. (C) mDC and IL-10 DC and IL-10 DC +/210
4 U/
mL IFN-a were generated as described in Materials and Methods. At day 7, supernatants were collected and production of IL-12 p40 was assessed by
ELISA. Mean values +/2 standard deviation (SD) of 4 independent experiments are shown; nd: not detected. * p,0.05; ** p,0.01; *** p,0.001, n.s.
not significant.
doi:10.1371/journal.pone.0022763.g001
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IL-10 were not produced in significant amounts by mDC and IL-
10 DC (data not shown) [16,23]. Nor did IFN-a treatment induce
secretion of IL-12p70 or IL-10 in both DC subsets (data not
shown).
IFN-a increased the stimulatory capacity of IL-10 DC
IL-10 DC are weak stimulators of T cell proliferation compared
to mDC [16,24] (Fig. 2A). This phenomenon is essentially
involved in differentiation of T cells into tolerogenic iTregs. In
order to investigate the accessory function of IFN-a-treated DC,
we performed a series of functional coculture experiments.
Notably, IFN-a treatment significantly increased the T cell
stimulatory properties of IL-10 DC, resulting in enhanced CD4
+
and CD8
+ T cell proliferation (Figure 2A).
Furthermore, IFN-a-DC provoked a significantly increased
effector cytokine production of stimulated T cells. We observed
enhanced levels of IFN-c by co-cultured CD4
+ T cells corre-
sponding to the restored T cell proliferation (Fig. 2B). CD4
+ T
cells primed with IL-10 DC exhibited increased levels of the
Figure 2. IL-10 DC generated in the presence of IFN-a induced an enhanced T cell activation. (A, B) CD4
+ or CD8
+ T cells were stimulated
in primary culture with allogeneic mDC, IL-10 DC or IL-10 DC cultured with 10
4 U/mL IFN-a. (A) T cell proliferation after restimulation was assessed as
described and pooled data of 6 (CD4
+ T cells) or 3 (CD8
+ T cells) independent experiments are demonstrated. Proliferation is demonstrated in % +/
2SD (normalized to 100% proliferation induced by control mDC). (B) IFN-c and IL-10 production were detected in the supernatants of CD4
+ T cells at
day 5 of primary culture by ELISA. Mean values of cytokine levels in pg/ml +/2 SD of 6 (IFN-c) or 5 (IL-10) independent experiments are shown.
*p ,0.05; ** p,0.01; n.s. not significant.
doi:10.1371/journal.pone.0022763.g002
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incubated with mDC. A further increase in IL-10 levels was
detected in supernatants of CD4
+ T cells primed with IFN-a-
treated IL-10 DC (Fig. 2B).
IFN-a treatment of IL-10 DC prevented anergy induction
in T cells
To figure out whether IFN-a treatment of IL-10 DC modulates
the capacity of tolerogenic DC to induce anergic T cells, we
analyzed T cell proliferation in restimulation experiments.
Proliferation of CD4
+ and CD8
+ T cells previously co-cultured
with IL-10 DC was significantly inhibited, demonstrating the
induction of an anergic T cell phenotype by IL-10 DC (Fig. 3A).
However, IFN-a-treatment of IL-10 DC resulted in a significantly
enhanced CD4
+ T cell response, indicating abrogation of T cell
anergy (Fig. 3A). Proliferation of CD8
+ T cells primed with IFN-a-
treated IL-10 DC was slightly but not significantly increased as
compared to stimulation by control IL-10 DC (Fig. 3A).
Analyses of IFN-c production after restimulation revealed that
treatment of IL-10 DC with IFN-a resulted in increased IFN-c
production of CD4
+ and CD8
+ T cells, indicating a Th1/Tc1
skewing (Fig. 3B).
Suppressor function of iTregs was abrogated after IFN-a
treatment of tolerogenic IL-10 DC
Next, we assessed the effect of IFN-a on the suppressor function
of anergic iTregs induced by IL-10 DC. Therefore, we analysed
the suppressor capacity of iTregs on the proliferation of cocultured
allogeneic CD4
+CD25
low effector T cells (Teff). As shown in
Fig. 3C, CD4
+CD25
high naturally occurring regulatory T cells
(nTregs) served as controls with high suppressor activity. As
reported previously, iTregs induced by IL-10 DC, significantly
suppressed the proliferation of cocultured Teff [17]. Importantly,
IFN-a treatment during the generation of tolerogenic IL-10 DC
significantly inhibited the suppressor function of iTregs primed by
these DC, indicating that IFN-a annihilates the tolerogenic
function of IL-10 DC and, therefore, the induction of anergic
iTregs (Fig. 3C).
IFN-a did not interfere directly with the induction or
maintenance of T cell anergy
As shown previously, IFN-a exhibits inhibitory effects on T cell
proliferation independent of the stimulating APC population or
the activating agent [25,26]. We addressed the question whether
IFN-a is also capable to inhibit DC-T cell interactions required for
induction of T cell anergy. In addition, we analyzed whether IFN-
a abolishes the maintenance of the anergic T cell phenotype. For
this purpose, T cells were incubated with IFN-a during primary
cultures with DC or during restimulation experiments, respective-
ly. As shown in Fig. 4A (left panel), IFN-a inhibited the T cell
proliferation in primary cultures induced by both, mDC and IL-10
DC in a dose-dependent manner. Normalization with regard to
the mDC-induced T cell proliferation (=100%) was calculated for
each IFN-a concentration and medium control. The results
revealed that the presence of IFN-a during DC-T cell interaction
did not affect the induction of T cell anergy (Fig. 4A, right panel).
Similar results were obtained when the influence of IFN-a on
the maintenance of the anergic T cell phenotype induced by
tolerogenic DC was analysed. As expected, restimulation in the
presence of IFN-a promoted a significant and dose-dependent
reduction of effector T cell proliferation (induced by mDC).
However, IFN-a did not affect the anergic state of CD4
+ T cells
(primed with IL-10 DC) as demonstrated for absolute values
(Fig. 4B, left panel) or percentages normalized to effector T cell
proliferation (=100%) (Fig. 4B, right panel). These results indicate
that IFN-a does neither inhibit the induction of T cell anergy nor
does it directly modulate the properties of anergic T cells induced
by IL-10 DC.
Discussion
In our study, we demonstrate that IFN-a abolishes the
tolerogenic phenotype of human IL-10 DC and, thereby, prevents
the induction of T cell anergy and regulatory T cells.
Tolerogenic DC can be induced by tumor- or immune cell-
derived factors like IL-10 and are critically involved in tumor
progression [11]. Previously, we have shown that addition of IL-10
during the generation of human DC induced a tolerogenic
phenotype of DC which provoked antigen-specific tolerance in
CD4
+ and CD8
+ T cells [16,19,27,28]. The induced anergic
iTregs inhibited activated effector T cell responses in an antigen-
specific fashion and induced a melanoma antigen-specific anergy
in CD8
+ cytotoxic T cells resulting in failure of tumor lysis. In the
present study, we show that IFN-a promotes the maturation of
tolerogenic IL-10 DC. However, addition of IFN-a to IL-10 DC
did not induce full maturation as triggered by supplementation of
a maturation cocktail. Similar observations have been made by
Santini et al. [3], demonstrating that IFN-a-induced generation of
DC resulted in an increased, but incomplete expression of the
maturation parameter CD83.
IFN-a is known to enhance the expression of the IL-12 receptor
b1a n db2 chains on human T cells enhancing Th1/Tc1 immune
responses, but, more dominantly, it negatively regulates IL-12 p40
and p70 production by APC [29,30,31]. Our study confirmed these
results by demonstrating that incubation of mDC as well as of IL-10
DC with IFN-a strongly inhibited IL12p40 secretion. As previously
reported, human monocyte-derived DC generated by the protocol
used in this study did not produce significant amounts of IL-12p70
[23]. Here, we demonstrated that IFN-a treatment did not increase
levels of IL-12p70 secretion. However, we found that IFN-a
stimulation of IL-10 DC was followed by an enhanced CD4
+ and
CD8
+ T cell proliferation and increased IFN-c levels, indicating an
amplified Th1/Tc1 cell response. If this effect is partially due to loss
of the immunosuppressive function of the IL-12 p40 subunit or of
the IL-23 heterodimer needs further evaluation [21]. In accordance
to our data, IFN-a-treated human DC have been shown to act as
effective APC in driving the development of Th1/Tc1 immune
responsesinvitroaninvivoand,morerecently,toexpandbothTh1
and Th17 populations [3,4,32,33].
In T cells, contradictory effects of IFN-a on proliferation,
function and cell death were observed [34,35,36,37,38]. It was
predominantly reported that IFN-a reduced the proliferative
response of CD4
+ T cells. The cytokine inhibits T cell proliferation
by targeting the MEK/ERK-pathway and by reducing suscepti-
bility and production of IL-2 [25,26]. In our hands, we confirmed
these results observing a dose-dependent impaired T cell
proliferation in the presence of IFN-a in primary cultures or
restimulation experiments. However, IFN-a did not restore the
anergic and regulatory phenotype of iTregs induced by tolerogenic
IL-10 DC, excluding T cells as target cells of IFN-a in our model
of tolerance. Intriguingly, IFN-a treatment abolished the induction
and suppressor function of iTregs by of tolerogenic DC. In line
with our results, in SLE patients, the activation and function of
naturally occurring CD4
+CD25
+FOXP3
+ Tregs were inhibited by
IFN-a, resulting in loss of tolerance [39,40]. Unlike these results,
IFN-a enhanced IL-10-induced differentiation of human func-
tional T regulatory type I (Tr1) cells [41].
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oncology [7]. Clinical treatment of melanoma patients with high
dose IFN-a is well established and direct antitumor effects as well
as modulation of the immune system are supposed to contribute to
the beneficial effect of the therapy [2,10]. In melanoma patients, a
striking correlation between the clinical response and the
development of autoimmune reactions has been demonstrated.
Reports of a prospective study of high dose IFN-a regime linked
the appearance of clinical and laboratory evidence for autoim-
munity with improved outcomes as demonstrated for relapse-free
and overall survival, assuming that IFN-a inhibits tolerance
mechanisms [42,43]. However, the impact of IFN-a on tolerance
mechanisms had not been addressed in detail. To date, the effects
of IFN-a on human tolerogenic DC are unknown, but there is
evidence that the ability of DC to attract Tregs, and thereby exert
inhibitory function, is imprinted during maturation of DC and
prevented by IFN-a [44]. Similar results were reported for
naturally occurring Tregs in a mouse model. This study
demonstrated that IFN-a inhibits the suppressor capacity of
murine nTregs via activation of APC [45]. These data are in line
with our observations that IFN-a treatment abolishes the
tolerogenic phenotype of human DC resulting in an inhibited
induction and function of anergic iTregs.
In our study, we demonstrated that addition of IFN-a during
the generation of tolerogenic IL-10 DC abrogated the tolerogenic
phenotype, enabled sufficient T cell responses with enhanced
Th1/Tc1-skewing and prevented from induction of anergic
iTregs. Tolerogenic DC in the tumor environment as well as in
the entire immune system substantially contribute to cancer
progression and metastasis. Our study indicates that one pivotal
effect of IFN-a treatment in melanoma patients may be the
reversal of tolerogenic DC into stimulatory APC to enhance
cancer control mechanisms.
Materials and Methods
Ethics statement
Human T cells and dendritic cells used in this study were
generated from buffy coats of healthy volunteers with approval of
the local ethics committee of Rhineland-Palatinate. A written
informed consent was obtained from all participants.
Culture medium
Iscoves MDM (PAA Laboratories, Pasching, Austria) supple-
mented with 2.5% autologous plasma was used for generation of
DC. T cells were cultured and stimulated in X-VIVO20 (Lonza,
Verviers, Belgum) supplemented with 0.5% autologous plasma.
Antibodies
For flow cytometry analysis, antibodies against CD2 (6F10.3),
CD14 (RM052), CD19 (J4.119), CD80 (MAB104), CD83
(HB15A) (all from Beckmann Coulter, Krefeld, Germany),
CD86, (BU63; Serotec, Raleigh, NC), HLA-DR (Serotec), and
mouse (MOPC-31-C, MOPC-173, and 27–35) and rat (A95-1,
R35-95) subclass–specific isotypes (BD Pharmingen, Heidelberg,
Germany) were used. As conjugated secondary reagents, FITC-
conjugated goat anti–rat IgG (Biolegend, San Diego, CA) and PE-
conjugated donkey anti–mouse IgG (Jackson Immunoresearch,
Bar Harbor, ME) were used. For staining of magnetic-activated
cell-sorter (MACS)–sorted T cells, FITC-conjugated CD4 (13B8.2)
or CD8 (B9.11) and FITC-conjugated mouse IgG (697.1Mc7) (all
from Beckmann Coulter) were used.
Generation of DC
Human DC were generated as described [24]. Briefly, PBMC
were isolated from buffy coats and non-adherent cells were cultured
in 3 mL Iscoves MDM supplemented with 400 U/mL granulocyte-
macrophage colony-stimulating factor GM-CSF) (Leukine; Bayer,
Seattle, WA), 150 U/mL IL-4 (Immunotools, Friesoythe, Germany)
and 2.5% autologous plasma. At day 5, nonadherent cells were
collected, resuspended in Iscoves MDM supplemented with 2.5%
autologous plasma, 400 U/mL GM-CSF and 150 U/mL IL-4, and
additionally stimulated with 2.5 ng/mL IL-1b,2 . 5n g / m LT N F - a
(Miltenyi Biotec, Bergisch-Gladbach, Germany), 25 U/mL IL-6
(Strathmann), and 0.5 mg/mL PGE2 (Minprostin; Cayman, An-
nArbor,MI)toinduceterminaldifferentiationofmatureDC(mDC).
Tolerogenic IL-10 DC were generated by addition of 20 ng/mL IL-
10 (DNAX, Palo Alto, CA USA) to the cytokine cocktail for the last
two days of culture. For IFN-a treatment, IL-10 DC were incubated
with 10
4 U/mL IFN-alpha (Roche, Basel, Switzerland) simulta-
neously to IL-10 during the last two days of culture.
Preparation of T cell populations
CD4
+ or CD8
+ T cells were prepared from buffy coats using
CD4- or CD8-MACS beads (MACS systems; Miltenyi Biotec)
according to standard protocols (purity.95%).
Induction and restimulation of iTregs and activated CD4
+
or CD8
+ effector T cells
DC and T cells were prepared as described above, and 5610
5
mDC or IL-10 DC +/2 IFN-a were cocultured with 5610
6 CD4
+
T cells per well in 3 mL X-VIVO20 supplemented with 0.5%
autologous plasma and 2 U/mL IL-2 (Proleukin, Chiron GmbH,
Ratingen, Germany) in 6-well plates for 5 days during primary
culture to induce effector T cells (Teffs, mDC) and iTregs (IL-10
DC). Proliferation assays were performed with 0.5610
5 T cells per
well and different numbers of allogeneic DC in X-VIVO20
supplemented with 0.5% autologous plasma and 2 U/mL IL-2 in
96-well plates and proliferation was measured at day 5 by [
3H]-
thymidine incorporation. After 3–5 days, restimulation experi-
ments were conducted with T cells (0.5610
5/well) stimulated by
1 mg/mL anti-CD28 mAb (BD Pharmingen) in 96-well plates
coated with 0.5 mg/mL anti-CD3 mAb (OKT3) in X-VIVO20
supplemented with 0.5% autologous plasma. After 72 h, prolifer-
ation was detected by [
3H]-thymidine incorporation.
Figure 3. IFN-a treatment of IL-10 DC abolished suppressor function of iTregs. (A, B) CD4
+ or CD8
+ T cells were cultured in primary culture
with allogeneic mDC, IL-10 DC or IL-10 DC treated with 10
4 U/mL IFN-a, respectively. Restimulation experiments were performed with anti-CD3/anti-
CD28. T cell proliferation is depicted in % (normalized to 100% proliferation induced by mDC). Mean values +/2 SD of 4 (CD4
+) or 3 (CD8
+ T cells)
independent experiments are shown. (B) Supernatants were obtained after 72 h and analyzed for IFN-c production by ELISA. One representative
experiment is demonstrated for CD4
+ and CD8
+ T cells, respectively. (C) Suppressor assay: CD4
+ T cells primed with allogeneic mDC (iTeff), IL-10 DC
(iTregs) or IL-10 DC treated with 10
4 U/mL IFN-a (iTregs + IFN-a), respectively, or freshly isolated CD4
+CD25
high nTregs were cocultured with
CD4
+CD25
low effector T cells and stimulated by 0.5 mg/mL anti-CD3 in the presence of irradiated PBMC. T cell proliferation was determined by [
3H]
thymidine incorporation. Suppressor activity is shown in proliferation of Teff + cocultured T cell population/poliferation of Teff 6100 in % +/2 SD.
One representative experiment of 3 is demonstrated. Results are shown in absolute cpm +/2 SD for triplicates. * p,0.05; ** p,0.01; *** p,0.001, n.s.
not significant.
doi:10.1371/journal.pone.0022763.g003
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PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e22763Figure 4. IFN-a did not interfere with priming or perpetuation of T cell anergy. (A) CD4
+ T cells were cocultured with allogeneic mDC or IL-
10 DC and incubated with concentrations of IFN-a as indicated. After 5 days, T cell proliferation was assessed by [
3H] thymidine incorporation, results
are depicted in absolute cpm +/2 SD (left panel) and in percentages +/2 SD (100%=T cell proliferation induced by mDC) (right panel). One
representative experiment of 3 is shown. (B) CD4
+ T cells primed with allogeneic mDC or IL-10 DC were restimulated with anti-CD3/anti-CD28 in the
presence of increasing concentrations of IFN-a as indicated. T cell proliferation was detected after 72 hours of restimulation as described. Results are
shown in absolute cpm +/2 SD (left panel) and in percentages +/2 SD (normalized to proliferation induced by mDC=100%) (right panel). One
representative experiment of 2 is demonstrated. n.s. not significant.
doi:10.1371/journal.pone.0022763.g004
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CD4
+ CD25
low effector T cells (Teff) and CD4
+CD25
+ nTregs
were isolated from buffy coats of healthy volunteers as described
before [46]. Briefly, CD25
+ cells were separated using limited
amounts of CD25-MACS-beads (Miltenyi Biotec) resulting in
CD25
high cells. Afterward, negative depletion of CD8
+, CD14
+
and CD19
+ cells was performed using CD8-, CD14- and CD19-
Dynabeads (Invitrogen, Darmstadt, Germany) (purity.85%). For
preparation of CD4
+CD25
low effector T cells (Teff), PBMC were
depleted of CD25
+ cells using CD25-MACS-beads and LD-
columns (Miltenyi Biotec) and subsequently, CD4
+ cells were
purified as described above. For suppressor assays, 1610
5 Teff and
1610
5 CD4
+CD25
+ nTregs or CD4
+ iTregs were co-cultured in
X-VIVO20 and stimulated with 0.5 mg/mL anti-CD3 mAb in the
presence of irradiated allogeneic PBMC (9000 rad, 90 Gy). Single
cultures of 1610
5 Teff, nTregs or iTregs served as controls. After
96 h proliferation was measured by [
3H]-thymidine incorporation.
Cytokine analysis
For assessment of cytokine production, supernatants were
collected at day 8 of DC culture, 120 h after coculture of DC
with T cells or 72 h after restimulation and stored at 270uC.
Amounts of IFN-c and IL-10 were assessed by ELISA using
commercially available antibodies and standards according to the
manufacturer’s protocols (Immunotools). Levels of IL-12p40 were
measured by ELISA using BD OptEIA Sets (Becton Dickinson).
Statistical analyses
Statistical significances of differences between experimental
groups were evaluated using the paired or unpaired Student’s t test
or the 1-way ANOVA and Tuckey’s Multiple Comparison test
and the GraphPadPrism 5 softwarepackage (Graphpad, La Jolla,
California). p values of 0.05 or less were considered significant.
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